The 4 most recent market catalysts affecting $PACB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
Pacific Biosciences Of California Approves Restructuring Plan To Align With Strategic Initiatives; Restructuring To Reduce Workforce By About 8%; Expects $30M-$40M Annualized Operating Expense Reduction By End Of 2027; Estimates $2M Pre-Tax Charges For Reduction In Force
Pacific Biosciences of California (PACB) is implementing a significant restructuring plan, including an 8% workforce reduction, to better align its resources with strategic initiat…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 75
Pacific Biosciences Lowers FY2026 Sales Guidance from $165.000M-$175.000M to $155.000M-$165.000M vs $166.790M Est
Pacific Biosciences (PACB) has announced a reduction in its sales guidance for fiscal year 2026, moving from an initial range of $165 million-$175 million to a new range of $155 mi…
Aug 5, 2026
Corporate Catalyst
Neutral
Impact 75
Pacific Biosciences of California Appoints Mark Van Oene As President, CEO, Effective Immediately, Succeeding Christian Henry
Pacific Biosciences of California (PACB) has announced a significant leadership change, with Mark Van Oene, the current COO, being appointed as the new President and CEO, effective…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 95
Pacific Biosciences Q2 Adj. EPS $(0.14) Misses $(0.13) Estimate, Sales $39.007M Miss $40.067M Estimate
Pacific Biosciences (PACB) announced its Q2 earnings, reporting an adjusted EPS of $(0.14) and sales of $39.007 million. Both figures fell short of analyst consensus estimates, wit…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.